Bionano Genomics (BNGO) Cost of Revenue (2017 - 2026)

Bionano Genomics has disclosed Cost of Revenue across 10 years of filings, most recently posting $3.9 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 18.46% year-over-year to $3.9 million; the TTM figure through Jun 2026 stood at $15.8 million (down 26.15% YoY), while the FY2025 annual figure was $15.3 million, down 49.59% from the prior year.
• Cost of Revenue came in at $3.9 million for Q2 2026 at Bionano Genomics, up from $3.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $14.5 million in Q3 2024 to a low of $157000.0 in Q4 2024.
• Average Cost of Revenue over 5 years is $5.4 million, with a median of $5.2 million recorded in 2022.
• Year-over-year, Cost of Revenue plunged 98.1% in 2024 and jumped 2799.36% in 2025.
• Over 5 years, Cost of Revenue stood at $6.4 million in 2022, then climbed by 29.22% to $8.3 million in 2023, then sank by 98.1% to $157000.0 in 2024, then jumped by 2799.36% to $4.6 million in 2025, then dropped by 15.27% to $3.9 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $3.9 million in Q2 2026, $3.4 million in Q1 2026, and $4.6 million in Q4 2025.